Walleye Capital LLC Increases Stake in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Walleye Capital LLC raised its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 758.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 234,506 shares of the life sciences company's stock after acquiring an additional 207,196 shares during the period. Walleye Capital LLC owned approximately 0.30% of Integra LifeSciences worth $4,261,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in IART. Blue Trust Inc. boosted its stake in Integra LifeSciences by 100.5% during the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company's stock worth $26,000 after acquiring an additional 444 shares in the last quarter. CWM LLC boosted its position in shares of Integra LifeSciences by 50.8% during the second quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock worth $37,000 after acquiring an additional 425 shares during the last quarter. KBC Group NV boosted its position in shares of Integra LifeSciences by 65.2% during the third quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock worth $52,000 after acquiring an additional 1,120 shares during the last quarter. Northwest Investment Counselors LLC purchased a new stake in Integra LifeSciences during the third quarter valued at approximately $73,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Integra LifeSciences in the 2nd quarter worth about $114,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on IART shares. Citigroup lifted their price target on Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a report on Tuesday, November 5th. Truist Financial dropped their price target on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a research report on Monday, October 14th. BTIG Research upgraded Integra LifeSciences from a "sell" rating to a "neutral" rating in a research note on Monday, October 7th. Bank of America cut their price target on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating on the stock in a research note on Monday, October 7th. Finally, Morgan Stanley started coverage on Integra LifeSciences in a report on Monday. They set an "underweight" rating and a $20.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company's stock. According to MarketBeat.com, Integra LifeSciences currently has an average rating of "Hold" and an average price target of $23.00.

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART remained flat at $24.58 during midday trading on Monday. 572,644 shares of the company were exchanged, compared to its average volume of 1,086,802. The stock has a market capitalization of $1.90 billion, a PE ratio of -273.11, a P/E/G ratio of 0.84 and a beta of 1.08. Integra LifeSciences Holdings Co. has a 52 week low of $16.81 and a 52 week high of $45.42. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The stock has a 50-day simple moving average of $20.77 and a 200 day simple moving average of $23.96.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.39 by $0.02. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $380.80 million during the quarter, compared to analyst estimates of $375.81 million. During the same quarter in the prior year, the firm earned $0.76 earnings per share. Integra LifeSciences's revenue for the quarter was down .4% on a year-over-year basis. Research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.